New hope for Tough-to-Treat blood cancer: experimental therapy battles aggressive lymphoma
NCT ID NCT04408638
Summary
This study compares two drug combinations for patients whose aggressive lymphoma has returned or stopped responding to previous treatments. Researchers are testing whether adding a new drug called glofitamab to standard chemotherapy works better and is safer than the current standard combination. The trial involves 270 participants and measures how long patients live, how long the cancer stays controlled, and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus Universitetshospital Skejby
Aarhus N, 8200, Denmark
-
Asan Medical Center
Seoul, 05505, South Korea
-
Baptist - MD Anderson Cancer Center
Jacksonville, Florida, 32207, United States
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 OYN, United Kingdom
-
CHU Pontchaillou
Rennes, 35003, France
-
CHU de Liège (Sart Tilman)
Liège, 4000, Belgium
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli
Lublin, 20-090, Poland
-
Chang Gung Medical Foundation - Kaohsiung;Oncology
Kaoisung, 833, Taiwan
-
Chang Gung Medical Foundation - Linkou
Taoyuan District, 333, Taiwan
-
Christie Hospital
Manchester, M20 4BX, United Kingdom
-
Chu de Montpellier-St Eloi
Montpellier, 34295, France
-
Community Cancer Institute (CCI)
Fresno, California, 93720, United States
-
Duke University Medical Center
Durham, North Carolina, 27705, United States
-
Fudan University Shanghai Cancer Center
Shanghai, 200120, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Henan Cancer Hospital
Zhengzhou, 450008, China
-
Hopital Claude Huriez
Lille, 59037, France
-
Hopital Henri Mondor
Créteil, 94010, France
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Clínic i Provincial
Barcelona, 08036, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hospital Universitario la Paz
Madrid, 28046, Spain
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Inselspital Bern, Insel-Gruppe AG
Bern, 3010, Switzerland
-
Institut Bergonie
Bordeaux, 33076, France
-
Instytut Hematologii i Transfuzjologii
Warsaw, 02-776, Poland
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Monash Health Monash Medical Centre
Clayton, Victoria, 3168, Australia
-
National Cancer Center
Goyang-si, 10408, South Korea
-
Nottingham City Hospital
Nottingham, NG5 1PB, United Kingdom
-
Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie
Olsztyn, 10-228, Poland
-
Peking University Third Hospital
Beijing, 100083, China
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Prince of Wales Hospital
Randwick, New South Wales, 2031, Australia
-
Pusan National University Hospital
Busan, 49241, South Korea
-
Rigshospitalet
København Ø, 2100, Denmark
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, 13605, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
-
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
-
St James's Institute of Oncology
Leeds, LS9 7TF, United Kingdom
-
St Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
-
Sun Yet-sen University Cancer Center
Guangzhou, 510060, China
-
Taichung Veterans General Hospital
Xitun Dist., 40705, Taiwan
-
Tianjin Cancer Hospital
Tianjin, 300060, China
-
UCLH - Clinical Trials Pharmacy B&D Centre
London, NW1 2PG, United Kingdom
-
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
-
Universitaetsklinikum Regensburg
Regensburg, 93053, Germany
-
Universitatsklinikum Frankfurt
Frankfurt, 60590, Germany
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294-3300, United States
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
-
University of Mississippi Medical Center
Jackson, Mississippi, 39216, United States
-
Universitätsklinikum Gießen und Marburg GmbH Standort Gießen Medizinische Klinik I
Giessen, 35392, Germany
-
Universitätsspital Zürich
Zurich, 8091, Switzerland
-
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
Wroc?aw, 50-367, Poland
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-214, Poland
-
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, 430022, China
-
Zhejiang Cancer Hospital
Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.